Skip to main content
VVOS
NASDAQ Life Sciences

Vivos治疗公司在内华达州获得广泛保险覆盖，400万美元的成本削减推动实现现金流正值

feedReported by GlobeNewswire
Sentiment info
Positive
Importance info
9
Price
$1.16
Mkt Cap
$11.933M
52W Low
$1.09
52W High
$7.95
Market data snapshot near publication time

summarizeSummary

Vivos治疗公司宣布，其在内华达州的专业医疗实践已获得多家商业医疗保险公司和Medicare的“网络内”状态，大大扩展了患者在关键市场获取其专利OSA治疗的机会。这一发展预计将大幅增加顶级收入和盈利能力。同时，公司正在实施成本削减计划，包括人员裁减，目标是通过重组其传统的口腔医疗焦点的分销模式，实现约400万美元的年度费用节约。这些综合努力预计将大大降低Vivos的现金烧钱率，并推进其在2026财年实现现金流正值的目标，对于这家小盘公司来说，这是一次关键的财务转型。投资者将关注这些成本节约的实际实现以及扩大保险覆盖对患者数量和收入增长的影响。

在该公告发布时，VVOS的交易价格为$1.16，交易所为NASDAQ，所属行业为Life Sciences，市值约为$1193.3万。 52周交易区间为$1.09至$7.95。 这则新闻被评估为积极市场情绪，重要性评分为9/10。 来源：GlobeNewswire。

show_chartPrice Chart

Share this article

Copied!

feed VVOS - Latest Insights

VVOS
Apr 22, 2026, 4:25 PM EDT
Filing Type: 8-K
Importance Score:
9
Vivos Therapeutics Receives Nasdaq Delisting Notice for Equity Deficiency
Sentiment: Negative
View Wiseek Article
VVOS
Apr 15, 2026, 5:05 PM EDT
Source: Wiseek News
Importance Score:
9
Vivos Therapeutics Reports Widened $(21.23)M Net Loss for 2025, Revenue Up 16%
Sentiment: Negative
View Wiseek Article
VVOS
Apr 15, 2026, 5:00 PM EDT
Filing Type: 10-K
Importance Score:
9
Vivos Therapeutics Reports Widened Net Loss, Negative Equity, and Going Concern Warning Amidst Nasdaq Delisting Risk
Sentiment: Negative
View Wiseek Article
VVOS
Apr 03, 2026, 4:05 PM EDT
Filing Type: 8-K
Importance Score:
9
Vivos Therapeutics Secures $2.39M in Dilutive Private Placement Amidst Nasdaq Delisting Warning
Sentiment: Negative
View Wiseek Article
VVOS
Apr 02, 2026, 7:34 PM EDT
Filing Type: 4
Importance Score:
9
10% Owner Michael Skaff and V-Co Investors 3 LLC Acquire $7.17M in Vivos Therapeutics Stock and Warrants
Sentiment: Positive
View Wiseek Article
VVOS
Apr 02, 2026, 6:32 PM EDT
Filing Type: SCHEDULE 13D
Importance Score:
8
V-Co Investors Group Acquires 19.9% Stake in Vivos Therapeutics via $2.39M Private Placement, Plans Active Engagement
Sentiment: Neutral
View Wiseek Article
VVOS
Mar 26, 2026, 8:45 AM EDT
Source: GlobeNewswire
Importance Score:
9
Vivos Therapeutics Secures Broad Nevada Insurance Coverage, $4M Cost Cuts Drive Path to Cash Flow Positive
Sentiment: Positive
View Wiseek Article
VVOS
Feb 13, 2026, 7:17 PM EST
Filing Type: S-3
Importance Score:
7
Vivos Therapeutics Registers 3.96M Shares for Resale by Institutional Investor Armistice Capital
Sentiment: Negative
View Wiseek Article
VVOS
Jan 20, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Vivos Therapeutics Secures $4.6M via Warrant Inducement, Issues New Dilutive Warrants
Sentiment: Negative
View Wiseek Article
VVOS
Jan 16, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
8
Vivos Therapeutics Secures Up to $5.5M Convertible Note with 10% Discount for Working Capital
Sentiment: Neutral
View Wiseek Article